Preemptive use of adjunctive IV lidocaine for enhanced recovery after abdominal hysterectomy for overweight and obese women: a prospective, randomized, double-blind, placebo-controlled study

Nahla Waer Shady1*, Hassan Ahmed Farouk1, Hany Farouk Sallam2

1Obstetrics and Gynecology Department, Aswan Faculty of Medicine, Aswan University, Aswan Governorate, Egypt
2Obstetrics and Gynecology Department, Mansoura Insurance Hospital, Mansoura, Egypt

Received: 08 January 2021
Accepted: 10 February 2021

*Correspondence:
Dr. Nahla Waer Shady,
E-mail: nahlagyn@yahoo.com

ABSTRACT

Background: This investigation planned to evaluate the clinical results of adjunctive IV lidocaine bolus dose plus infusion for one hour after surgery in patients who underwent an abdominal hysterectomy in obese and overweight women.

Methods: We performed a double-blind, placebo-controlled study, (ClinicalTrials.gov identifier: NC03748108), with patients undergoing abdominal hysterectomy divided into 2 groups: one group received intravenous lidocaine single bolus dose preoperatively and IV infusions till one hour after the surgical procedure, and the opposite received normal saline infusion (placebo). We assessed postoperative results, including pain scores rankings on a visual analog scale (VAS) in rest and movement, administration frequency of pethidine. Postoperative nausea and vomiting, the period of hospital stay (LOS), time to ambulate, and patient satisfaction at forty-eight hours had been evaluated. Chi-square test and Monte Carlo test have been used for comparison among groups.

Results: There were 120 patients in our study. The visual analog scale (VAS), pain scores, length of hospital stay (LOS), and administration frequency of pethidine were significantly lower in the lidocaine group. The total amount of consumed pethidine was significantly lower in the lidocaine than the placebo group. There was a significant reduction in post-operative pain which was assessed by visual analog scale (VAS) after 2, 4, 8, 12, and 24 hours either during movement or during rest in the lidocaine group compared to the placebo group, p=(0.0001, 0.0001, 0.0001, 0.0001 and 0.0001).

Conclusions: The administration of adjuvant intravenous lidocaine infusion reduces pain during the postoperative period after abdominal hysterectomy, is associated with early recovery, decreased postoperative opioid analgesic requirement, and better patient satisfaction in overweight and obese women undergoing abdominal hysterectomy.

Keywords: Abdominal hysterectomy, Enhanced recovery, IV lidocaine

INTRODUCTION

Pain is a common problem after abdominal hysterectomy and may interfere with early movement and recovery. Therefore, the reduction of postoperative pain would enhance patient recovery postoperatively.1

Postoperative pain results because of releases of inflammatory, visceral, and neuropathic mediators because of surgical trauma creating anatomical and functional changes in pain pathways coming about in hyperalgesia and central sensitization. Successful relief of pain is the foundation of recovery from surgery.2
The prevalence of obesity described as a body mass index (BMI) ≥30 kg/m² is more prominent than 30% and maintains on growing (3). Obesity is associated with beneficial technical difficulties and improved patient morbidity after open hysterectomy. Expanding BMI is associated with prolonged operative time, longer nonsurgical room time, higher assessed blood loss, and other operative complications.4,5

Current records have shown that the hazard of taking chronic opioids after surgical treatment will increase after approximately five days of postoperative opioid remedy.6,7 Limitation the use of narcotics is desirable, especially those with few or no systemic adverse drug effects (ADEs), and lidocaine is one such perioperative multimodal agent that has been used clinically for many years.

Effective nonopioid analgesics regarded to lessen opioid consumption after gynecologic surgery include pregabalin, gabapentin, nonsteroidal anti-inflammatory drugs, cyclooxygenase 2 inhibitors, and paracetamol.8 Lidocaine is an amide neighborhood anesthetic whose mechanism of action is the blockade of voltage-gated sodium channels and due to its enormously low efficiency compared to other nearby anesthetics, it is less toxic at clinically relevant doses than others, such as bupivacaine and ropivacaine.9

Our hypothesis that the use of adjunctive IV lidocaine as a bolus dose pre-operative followed with IV infusion one-hour post-operative with other non-opioid analgesia enhances obese and overweight women recovery after abdominal hysterectomy. This study aimed to assess the clinical effect of preemptive use of adjunctive intravenous lidocaine IV bolus dose plus infusion for one hour after surgery in obese and overweight women patients who underwent abdominal hysterectomy.

METHODS

The current study is a clinically registered double-blinded, parallel, randomized trial (ClinicalTrials.gov identifier: NC03748108), conducted in a tertiary university hospital, from December 1, 2018, to August 1, 2020. The institutional ethical review board approved the study (Aswu/203/2/18).

Inclusion criteria

Study inclusion criteria were overweight and obese women who underwent total abdominal hysterectomy (TAH) with or without bilateral salpingoo-oophorectomy (BSO) due to myoma, menorrhagia, metrorrhagia, and endometrial hyperplasia.

Exclusion criteria

Patients with cardiac, hepatic, renal, or thromboembolic disease; patients with pelvic endometriosis and adnexal mass; patients with endometrial or cervical cancer, patient with an allergy to local anesthetic, and patients with chronic pelvic pain.

Eligible participants

150 patients were asked to participate, 30 patients were excluded, 24 patients not meeting inclusion criteria, and 6 patients refuse to participate. Therefore, the remaining 120 patients were included in the study.

All participants underwent detailed history, general, abdominal, and vaginal examinations, body mass index (BMI) was calculated, and pelvic ultrasound examination and preoperative hemoglobin were undertaken for all participants (Figure 1).

![Figure 1: Flowchart of the study.](image-url)
Randomization

Patients were randomized to two groups, each comprising of 60 patients according to a two-blocked randomization list which was coded (1 or 2) at a 1:1 ratio. The two equal groups were prepared using a computer-generated randomization framework. The assigned groups will be concealed in sequentially numbered fixed hazy envelopes that might be opened after enrollment.

Patient allocation will be performed before the induction of anesthesia by a free individual, who will not in any case be associated with this investigation. Participating patients, surgeons, anesthesiologists, and medical investigators who were involved in the data collection were all blinded to the patient’s group assignment until the collection of data for all cases was complete.

Intervention

In all eligible participants, the hysterectomies were performed by the same operative team. Patients were randomized to two groups, Group (1) 60 patients received normal saline infusion (placebo) single bolus dose 1.5mg/kg saline preoperatively and IV infusion 2mg/kg/h till one hour after the surgery.

Group (2) 60 patients received intravenous lidocaine single bolus dose 1.5 mg/kg lidocaine 2% preoperatively and IV infusion 2mg/kg/h till one hour after the surgery.

Prophylactic antibiotic (cefazolin 1g or ceftriaxone 1g) was given 30 min before scrubbing of the patient. The hemostatic strategy during surgery was done by conventional stitch ligature, using vicryl stitches (Vicryl 1-0 polyglactin; Egycryl, Taisier CO, Egypt) only.9,10

The abdomen was exposed through Pfannenstiel incision, and after skin incision, the subcutaneous fat and abdominal fascia were opened crosswise, and the rectus muscle was opened on the midline. Total hysterectomy with or without bilateral salpingo-oophorectomy was done. Anesthesia protocol and surgical procedure were the same in both groups.

Anesthesia was initiated quickly with intravenous thiopental (5 mg/kg) and succinylcholine (1.5 mg kg1); at that point, a cuffed endotracheal tube was inserted. Anesthesia continued with a mixture of 50% NO, 50% O2, and 0.5 to 0.75 MAC isoflurane at a flow of 5 L min1. Paralysis was maintained with 0.5 mg kg1 atracurium. Anesthesia was augmented by administering 100 kg fentanyl and 2 mg midazolam while continuing the volatile anesthetic. All ladies got 3 mg of intravenous morphine at the end of the operation.

Before surgery, eligible women were instructed by a nurse anesthetist and a final year medical student on how to rate their pain during rest and movement on a visual analog scale (VAS) at 2, 4, 8, 12, and 24 h after their operation. VAS ranges from 0 (no pain) to 10 (most intense pain ever).

VAS recordings were translated into numerical pain scores by the medical student. Women were administered a 100 mg diclofenac suppository every 8 hours after surgery and were administered pethidine 3 mg each time when they reported a VAS score higher than 5 cm. At 48 h post-operation, participants were asked whether they were satisfied with their pain control. Answers recorded just as 'Yes' or 'No.'

Study outcome

VAS pain score levels during the 24 h after surgery was the primary endpoint of the study. The secondary outcomes were estimation of hospital stay, amount of postoperative opioid in form of pethidine, early ambulation from bed within 8 hours, time for both bowel movement and getting out of the first flatus, operative time, patient satisfaction with their pain control and side effects of lidocaine.

Sample size

The size of the study was based on detecting a difference of 1 in the mean VAS scores at 24 h post-operation between the two groups. With a two-tailed an of .05 and a power of 90%, we needed 56 participants in each group. Expecting a maximum loss-to-follow-up of 5%, we decided to recruit 60 participants in each group.

Statistical Analysis

Data were entered and statistically analyzed using the Statistical Package for Social Sciences (SPSS) version 16. Qualitative data were described as numbers and percentages. Chi-square test and Monte Carlo test were used for comparison between groups, as appropriate. Quantitative data were described as means (SD) or medians, as appropriate.

They were tested for normality by the Kolmogorov-Smirnov test. In the normally distributed variables, one-way ANOVA with LSD posthoc multiple comparisons was used for comparison between groups. In the non-normally distributed variables, the Kruskal-Wallis test and Mann Whitney test were used for comparison between groups, as appropriate. Odds ratios and their 95% confidence interval were calculated. "p-value ≤0.05" was considered to be statistically significant.

RESULTS

Our study started with 150 patients who were asked to participate, 30 patients were excluded, 24 patients not meeting inclusion criteria and 6 patients refuse to participate. Therefore the remaining 120 patients were randomized to 2 groups each group comprised of 60
patients. Group I: (placebo group, undergone hysterectomy with a bolus dose of 1.5mg/kg normal saline just before anesthesia +2mg/kg maintenance dose for 1 hour postoperative ). Group II: ( lidocaine group, undergone hysterectomy with a bolus dose of lidocaine (1.5 mg/kg) just before anesthesia and maintenance dose (2 mg/kg) for 1 hour postoperative). There was no significant difference between the two groups corresponding to their age, weight, Hight, body mass index (BMI), uterine size, history of the previous scar, initial hemoglobin, and indication of hysterectomy (Table 1).

Table 1: Preoperative characteristics of women in the study groups.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Group I (n=60)</th>
<th>Group II (n=60)</th>
<th>Significance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (year)</td>
<td>50.08±5.44</td>
<td>50.2±5.15</td>
<td>0.852</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>87±7.9</td>
<td>86.4±7.6</td>
<td>0.428</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>163.73±4.16</td>
<td>163.42±4.47</td>
<td>0.752</td>
</tr>
<tr>
<td>BMI</td>
<td>28.86±2.76</td>
<td>28.7±2.39</td>
<td>0.732</td>
</tr>
<tr>
<td>Previous scar (%)</td>
<td>22 (36.7)</td>
<td>21 (35)</td>
<td>0.651</td>
</tr>
<tr>
<td>Uterus size (weeks)</td>
<td>13.17±3.38</td>
<td>13.17±3.22</td>
<td>0.831</td>
</tr>
<tr>
<td>Initial hemoglobin indication of hysterectomy (%)</td>
<td>10.38±0.80</td>
<td>10.34±0.84</td>
<td>0.627</td>
</tr>
<tr>
<td>AUB</td>
<td>23 (38.3)</td>
<td>21 (35)</td>
<td></td>
</tr>
<tr>
<td>Adenomyosis</td>
<td>8 (13.3)</td>
<td>7 (11.7)</td>
<td></td>
</tr>
<tr>
<td>Endometrial hyperplasia</td>
<td>9 (15)</td>
<td>8 (13.3)</td>
<td>0.923</td>
</tr>
<tr>
<td>Endometrial polyp</td>
<td>3 (5)</td>
<td>5 (8.3)</td>
<td></td>
</tr>
<tr>
<td>Myoma</td>
<td>17 (28.3)</td>
<td>19 (31.7)</td>
<td></td>
</tr>
</tbody>
</table>

BMI (body mass index), AUB (abnormal uterine bleeding), # Variables are presented as mean and standard deviation, and number (percentage).

Table 2: postoperative outcome in the study groups.

<table>
<thead>
<tr>
<th>Variables</th>
<th>Group I (n=60)</th>
<th>Group II (n=60)</th>
<th>Significance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Operative time</td>
<td>94.42±9.7</td>
<td>95.12±10.07</td>
<td>0.764</td>
</tr>
<tr>
<td>Hospital stay (median)</td>
<td>3 (2-4)</td>
<td>2 (1-3)</td>
<td>0.0001*</td>
</tr>
<tr>
<td>Pethidine consumption (%)</td>
<td>49 (81.7)</td>
<td>19 (31.7)</td>
<td>0.0001*</td>
</tr>
<tr>
<td>Early ambulation (%)</td>
<td>18 (30)</td>
<td>40 (66.7)</td>
<td>0.0001*</td>
</tr>
<tr>
<td>Bowel movement</td>
<td>14.92±3.54</td>
<td>9.58±2.17</td>
<td>0.0001*</td>
</tr>
<tr>
<td>First flatus</td>
<td>33.14±6.43</td>
<td>17.47±3.49</td>
<td>0.0001*</td>
</tr>
<tr>
<td>Patients satisfaction (%)</td>
<td>19 (31.7)</td>
<td>49 (81.7)</td>
<td>0.375</td>
</tr>
<tr>
<td>Distention (%)</td>
<td>5 (8.3)</td>
<td>2 (3.3)</td>
<td>0.375</td>
</tr>
<tr>
<td>Fever (%)</td>
<td>2 (3.3)</td>
<td>1 (1.7)</td>
<td>0.775</td>
</tr>
<tr>
<td>Nausea (%)</td>
<td>3 (5)</td>
<td>4 (6.7)</td>
<td>0.909</td>
</tr>
<tr>
<td>Vomiting (%)</td>
<td>2 (3.3)</td>
<td>1 (1.7)</td>
<td>0.775</td>
</tr>
<tr>
<td>Diarrhea (%)</td>
<td>1 (1.7)</td>
<td>0 (0)</td>
<td>1</td>
</tr>
</tbody>
</table>

*Statistically Significant Difference, # Variables are presented as mean and standard deviation, median (minimum-maximum), and number (percentage).

There was a great significant reduction in post-operative pain which was assessed by visual analog scale (VAS) after 2,4,8,12 and 24 hours either during movement or during rest in group II compared to group I, p=(0.0001, 0.0001, 0.0001, 0.0001 and 0.0001) (Table 2).Group II showed a significant decrease in hospital stays with a median of 2 days compared to the median 3 days in group I, p=(0.0001). Also group II consumed less amount of postoperative opioid in form of pethidine, 19 (31.4%) patients compared to 49 (81.7%) patients in group I, p=(0.0001).
The incidence of early ambulation from bed within 8 hours was increased in group II 40 (66.7%) patients compared with 18 (30%) patients in group I, p= (0.0001). There was a significant reduction in time for both bowel movement and getting out of the first flatus in group II compared with group I, as the mean hours of bowel movement was (9.58±2.17) in group II despite (14.92±3.54) in group I, and the mean hours of getting out the first flatus were (17.47±3.49) in group II compared to (33.17±6.43) in group I, p=(0.0001 and 0.0001). Also, no of patients satisfied with their pain was a significant increase in lidocaine group 49(81.7%) patients compared to 19(31.4%) patients in the placebo group. p=0.0001).

There were no significant differences concerning operative time and side effects in form of abdominal distention, fever, nausea, vomiting, and diarrhea in both groups. p=(0.764, 0.375, 0.775, 0.909, 0.775 and 1.00) respectively Table (3).

**DISCUSSION**

There are 4 unique aspects of the ERAS protocol after surgical treatment, anesthetic desire, nonopioid multimodal pain control, postoperative nausea, and vomiting (PONV) prevention strategies, and fluid control. In the hour study, we examine the adjuvant lidocaine to the nonopioid analgesia to enhance the recovery of the obese and overweight affected person undergoing abdominal hysterectomy.

Our principal finding was that adjunctive bolus dose plus IV infusion of lidocaine may provide improvement in pain ratings in the perioperative period, decrease in-hospital stay, less amount of postoperative opioid in the form of pethidine, more early ambulation from bed within 8 hours, reduction in time for both bowel movement and getting out of the first flatus compared with placebo in overweight and obese women undergoing abdominal hysterectomy.

These findings demonstrate that lidocaine can be used to enhance recovery and reduce postoperative pain. To the best of our knowledge, this study is the first double-blind randomized placebo-controlled trial comparing the effectiveness of adjunctive bolus dose plus IV infusion of lidocaine versus placebo for enhanced recovery after abdominal hysterectomy for overweight and obese women.

There are varied ways by which intravenous lidocaine lessens the postoperative pain and enhance the recovery process in the perioperative period. Also, has been broadly detailed and is multifactorial. Expansion in a grouping of acetylcholine in cerebrospinal liquid, prompting worsening of inhibitory sliding pain pathway, (10) hindering of muscarinic receptors M5, restraint of glycine receptors, arrival of endogenous opioids, decrease of the incendiary reaction to tissue ischemia, and diminished arrival of cytokines because of tissue damage, are a portion of the components proposed for the pain-relieving impacts of lignocaine implantation.7,10-14 Lidocaine is additionally answerable for an immediate or backhanded decrease of postsynaptic depolarization interceded by N methyl D aspartate receptors.15

Our results were also following findings from Tausin Fin and Bernard who examined the impact of adding lidocaine infusion to standard anesthesia protocol in an aggregate of 47 patients admitted in two phases and planned for laparoscopic nephrectomy. Lidocaine infusion was continued for 24 h postoperatively and was associated with significantly reduced morphine consumption and postop pain score and hyperalgesia extent on days 1, 2, and 4 postoperatively. Brief walk test and entry of first flatus were additionally altogether improved in quite a while getting iv lidocaine infusion. Comparative outcomes were seen by Kim et al. and by Yon et al.16-18 Meta-analyses and systematic reviews detailed that IV lidocaine infusions diminished postoperative pain, diminished narcotic utilization, prompted a quicker return of bowel function, and abbreviated hospital length of stay in abdominal surgeries.19,20 However, investigations of patients going through open hysterectomy have not demonstrated advantages in reducing pain scores, narcotic utilization, improving quality of recovery, or shortening hospital stays, except for some reduction in inflammatory mediators and pain scores in the early postoperative period in 1 study.21-23 The absence of pain-relieving advantage might be because the lidocaine infusions were utilized uniquely in the intraoperative period in these studies. In our study, we extend the lidocaine infusion for one hour’s post-operative. Albeit numerous studies of other abdominal surgeries proceeded with the lidocaine implantation in the postoperative period, a few examinations likewise detailed advantage after administration just in the intraoperative period.12

Opioid-sparing analgesic regimens are believed to be a crucial part of an ERAS protocol, due to the fact opioids had been implicated in immunosuppression, postoperative hyperalgesia, submit-operative nausea, and vomiting (PONV), paralytic ileus, and delay of early mobilization due to sedation. Our study display that using adjunctive lidocaine lessens the amount of postoperative opioid administration. Our study shows a reduction in time for both bowel movement and getting out of the first flatus compared with placebo.

Postoperative ileus is a typical purpose behind an extended hospital stay after abdominal hysterectomy, even when the surgical procedure straight forward without complication. Its pathophysiology is multifactorial. Arrival of inflammatory mediators during surgery, huge volume fluid resuscitation, increase the time of surgery, and postoperative utilization of narcotics for analgesia have been hypothesized as elements liable
for ileus. Sedative agents, for example, narcotics are believed to be among the causal components. To lessen the stress response, the utilization of IV lidocaine has been advocated. This provides better postoperative pain control and decreases surgical stress. Moreover, it shortens the length of postoperative ileus.24-26

Early return of bowel function was hypothetical as unite of the criteria for fast track surgery and early discharge from hospital. Lidocaine through its effects on proinflammatory mediators was responsible for early bowel function after surgery.27,28 This effect was, however, in contrast to our result, not seen in patients undergoing peripheral and abdominal surgeries.29,30 Our study is in line with De Oliveira et al. who state that the utilization of intravenous lidocaine enhances the fast-track surgery.31

One of the strengths of our study is that a double-blinded randomized trial full power to advocate the application of bolus dose of lidocaine plus iv infusion for one hour postoperative as an adjuvant to non-opioid analgesia effective for early recovery after abdominal hysterectomy in overweight and obese women. Another strength in our study is the simplicity of the technique of administration of lidocaine.

One of our limits of the study is the use of general anesthesia and not use of regional anesthesia, however no RCTs are delineating the ideal intraoperative anesthetic protocol to guide ERAS ideas, even in guidelines already installed for colorectal surgical procedure. Regardless, intraoperative neuraxial anesthesia has been implemented in multiple fast-track protocols because of proven benefits on attenuating the physiologic surgical stress response and showing narcotic saving impacts. Future studies are needed to delineate the post-operative benefit of lidocaine in adjunctive with regional anesthesia to enhance early recovery after gynecological surgery.

CONCLUSION

Intravenous lidocaine infusion reduces pain during the postoperative period after abdominal hysterectomy, is associated with early recovery, decreased postoperative analgesic requirement, and better patient satisfaction.

Recommendations

The purpose of this study was to describe the evidence for the benefits of Intravenous lidocaine infusion after surgery in patients who underwent an abdominal hysterectomy in obese and overweight women, our result indicates that intravenous lidocaine infusion reduces pain during the postoperative period after abdominal hysterectomy, is associated with early recovery, decreased postoperative analgesic requirement, and better patient satisfaction.

ACKNOWLEDGMENTS

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: The study was approved by the Institutional Ethics Committee

REFERENCES

13. Vigneault L, Turgeon AF, Côté D. Perioperative intravenous lidocaine infusion for postoperative pain